Jobs / United States / Pfizer INC
Principal Scientist, In vivo Pharmacology, Neuroinflammation/Neurodegeneration
Pfizer INC · 🇺🇸 United States - Massachusetts - Cambridge
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 40 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 9 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Pfizer INC paid sponsored hires in similar roles3 certified filings for “SENIOR SCIENTIST” (Biochemists and Biophysicists) in MA: $128k–$153k, median $132k. Most were filed at wage level III (67%) — 3 lottery entries, ≈46% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Pfizer INC
The US Department of Labor certified 40 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 9 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Pfizer INC →
About the role
Position Purpose The Pfizer Inflammation & Immunology Research Unit (I&I RU) in Cambridge, MA, is seeking an experienced Principal Scientist (R5) to join the in vivo pharmacology group as a subject matter expert and scientific leader. In this senior role, you will lead the preclinical in vivo pharmacology strategy focused on neuroinflammatory mechanisms in Alzheimer’s disease and related neurodegenerative disorders. You will serve as both a conceptual driver and a technical authority—responsible for designing, directing, and critically interpreting in vivo, ex vivo, and complementary in vitro studies that elucidate disease biology and establish target engagement, pharmacodynamics, and therapeutic efficacy. Beyond core study design, you will spearhead the establishment of next-generation mouse models and advanced behavioral and physiological endpoints, lead cross-functional drug discovery project teams, mentor scientific staff, and champion innovative scientific avenues to fuel Pfizer’s preclinical neurodegeneration and neuroinflammation pipeline. This position offers an opportunity to drive impactful research in neuroinflammation while collaborating closely with multidisciplinary project teams to advance therapeutic discovery. Primary Responsibilities • Strategic Scientific & Program Leadership: Project Team Leadership : Serve as the in vivo pharmacology lead on multidisciplinary project teams, Pipeline Innovation : Act as an authoritative resource to explore, identify, and champion new preclinical biological concepts, External Collaborations : Interface with academic leaders, industry consortia, and contract research organizations (CROs) to evaluate new technologies and externalize specialized in vivo study execution when needed. • In Vivo Model Innovation & Experimental Strategy: Study Design & Oversight : Conceive, design, optimize, and oversee robust in vivo pharmacology studies, Model Establishment: Pioneer and validate cutting-edge rodent disease models, Readout Development : Implement and standardize state-of-the-art behavioral and physiological readouts to enhance translational predictive power. • Data Governance, Communication & Compliance: Data Synthesis & Reporting : Lead rigorous data analysis, statistical evaluation, synthesis, and documentation, Regulatory & Documentation : Author and review preclinical study reports, regulatory submission components and animal care protocols (IACUC), Animal Welfare & Compliance : Maintain the highest standards of data integrity, biosafety, and compliance with institutional animal care guidelines and 3Rs principles (Replace, Reduce, Refine). Technical and Scientific Requirements • Neuroinflammation & Neurodegeneration: Deep foundational knowledge of neuroinflammatory pathways, neuroimmune-glial crosstalk (microglia/astrocytes), and Alzheimer’s disease pathophysiology. • In Vivo Pharmacology Mastery: Demonstrated track record of designing, executing, and troubleshooting preclinical rodent pharmacology studies, target engagement assays, and PK/PD modeling in neuroscience or immunology. • Model & Readout Innovation: Proven experience in establishing and validating new animal models and developing complex behavioral, physiological, or imaging endpoints. • Analytical Techniques: Proficient understanding of multidimensional ex vivo analytical techniques (e.g., immunohistochemistry/immunofluorescence, quantitative image analysis, flow cytometry, gene expression profiling, cytokine quantification). • Drug Discovery Acumen:Demonstrated familiarity with early drug discovery pipelines (small molecules, biologics, and/or RNA-based therapeutics). Qualifications: • Ph.D. in Neuroscience, Pharmacology, Neurobiology, or a related biomedical science with 5+ years of relevant post-doc